Format

Send to

Choose Destination
Best Pract Res Clin Endocrinol Metab. 2016 Jan;30(1):103-14. doi: 10.1016/j.beem.2015.10.005. Epub 2015 Oct 8.

Peptide receptor radionuclide therapy of neuroendocrine tumours.

Author information

1
Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. Electronic address: t.brabander@erasmusmc.nl.
2
Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. Electronic address: j.teunissen@erasmusmc.nl.
3
Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands. Electronic address: c.vaneijck@erasmusmc.nl.
4
Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands. Electronic address: g.franssen@erasmusmc.nl.
5
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. Electronic address: r.feelders@erasmusmc.nl.
6
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. Electronic address: w.w.deherder@erasmusmc.nl.
7
Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. Electronic address: d.j.kwekkeboom@erasmusmc.nl.

Abstract

In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised or inoperable disease is peptide receptor radionuclide therapy (PRRT). This therapy involves an infusion of somatostatin analogues linked to radionuclides like Yttrium-90 or Lutetium-177. Objective response rates are reported in 15-35%. Response rates may vary between type of tumour and radionuclide. Besides the objective response rate, overall survival and progression free survival increase significantly. Also, the quality of life improves as well. Serious side-affects are rare. PRRT is usually well tolerated, also in patients with extensive metastasised disease. Recent studies combined PRRT with other types of therapies. Unfortunately no randomised trials comparing these strategies are available. In the future, more research is needed to evaluate the best therapy combinations or sequence of therapies.

KEYWORDS:

PRRT; neuroendocrine tumours; radionuclides; somatostatin receptor

PMID:
26971847
DOI:
10.1016/j.beem.2015.10.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center